POZ - XVI International AIDS Conference (2006) : IAC: Four Drugs Vs. Three - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Conference Coverage » XVI International AIDS Conference (2006)

emailrssprint

IAC: Four Drugs Vs. Three
by Tim Horn

August 14, 2006 (AIDSmeds)—Is a four-drug regimen any more effective than the current three-drug standard? Not according to a recent study reviewed at the XVI International AIDS Conference in Toronto.

"We saw no differences over three years between a four-drug regimen and a three-drug regimen in terms of decreasing viral load, increasing CD4 cells (T cells), or side effects," said Roy Gulick, MD, MPH, of Weill Cornell Medical College in New York.

"These findings suggest that current triple-drug therapies continue to perform remarkably well for the large majority of patients," according to Dr. Gulick. "For these patients, adding a fourth drug provided no added benefit."

The findings, based on an AIDS Clinical Trials Group study involving 765 HIV-positive people, were recently published in the Journal of the American Medical Association (JAMA) and were reviewed by Dr. Gulick at a press briefing sponsored by the American Medical Association on Sunday in Toronto.

Dr. Gulick explained the rationale for conducting this study. "Researchers initially discovered that two drugs together worked better than one, and then that three-drug regimens worked better than two-drug regimens," he said. "With each additional medication, we saw decreased progression to AIDS and decreased deaths. However, an open question was whether four drugs would work better than three."

In this randomized, double-blind, placebo-controlled study, approximately half of the patients – all of whom were starting therapy for the first time – received a triple-drug regimen consisting of Sustiva® (efavirenz) plus the two-drug combination tablet Combivir® (containing zidovudine and lamivudine). The other half of the patients took a four-drug regimen consisting of Sustiva plus the three-drug combination tablet Trizivir® (containing zidovudine, lamivudine, and abacavir). "Whether you got the three- or four-drug regimen, you still took the same number of pills per day. That means the four-drug regimen was no more complicated than standard triple therapy."

Dr. Gulick and his colleagues looked at three important parameters during the three-year study period: time to virologic failure (i.e., a rebound in viral load), changes in CD4 counts, and serious side effects.

As reviewed by Dr. Gulick, 26% of participants on the three-drug combo reached virologic failure, compared to 25% of those on the four-drug combo. The average time to virologic failure was also similar between the two groups.

After three years of treatment, approximately 85% of patients in the three-drug group had viral loads below 50, compared to 88% of those in the four-drug group.

There was also no significant difference between the two treatment arms in terms of CD4 counts or the incidence of side effects.

Why doesn't adding a fourth drug seem to matter? According to Dr. Gulick, "it seems that our current triple-drug therapies are already so effective that it's just hard to improve on that. In that sense, we're doing incredibly well." However, he explained that there are many exceptions to the rule. "Some patients with HIV do take a fourth medication," he said. "Even five- or six-drug regimens are not unheard of in patients with past treatment experience."


Source:
Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection. JAMA 296(7):769-81, 2006.

emailrssprint


[Go to top]

POZ Exclusives

Sexy ‘Fashion Roars’ Fundraiser for Generation Ubuntu

The Treatment Divide: When’s the Best Time to Start HIV Meds?

(RED) and Moleskine Join Forces to Fight AIDS

» More

What's That Mean?
(just double-click it!)

NEW! If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:


What You're Talking About

Mouth Full of Problems: A Crisis in HIV Dental Care (24)

Sex Crime (23)

HPV Vaccine for Boys: Public Comments Welcome (18)

Sir Elton John Denied Request to Adopt HIV-Positive Ukrainian Child (13)

HIV-Positive Sailor Sentenced for Consensual, Unprotected Sex (8)

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.